- Home
- BCAB vs PLX Comparison
BCAB vs PLX Comparison
Compare BCAB & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | PLX |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 182.9M |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | BCAB | PLX |
|---|---|---|
| Price | $3.81 | $2.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 50.2K | ★ 751.8K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.86 | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | $300,000.00 | ★ $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.81 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.12 | $1.52 |
| 52 Week High | $6.52 | $3.19 |
Technical Indicators
Market Signals| Indicator | BCAB | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 49.41 |
| Support Level | $0.17 | $2.18 |
| Resistance Level | $4.24 | $2.43 |
| Average True Range (ATR) | 0.32 | 0.12 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 36.69 | 33.64 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.